COMBINATION OF REFAMETINIB AND CETUXIMAB IN METASTATIC COLORECTAL CANCER TO PREVENT RESISTANCE.
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2533411
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: ARES trial seeks to establish whether a double blockade of the EGFR/MAPK pathway, achievable by combining cetuximab with the MEK inhibitor refametinib, could prevent or treat EGFR-directed secondary resistance in metastatic colorectal cancer. for ARES 0: Define the RP2D of refametinib + CET for ARES 1: Shift 35% of the SD patients in the OR category.for ARES 2: Increase Disease Control rate from 15% to 40%
Primary endpoints: for ARES 0: DLTs cycle 1 TRAEs by NCI-CTCAE v 4.0for ARES 1: Tumor response by RECIST v1.1for ARES 2: Disease control by RECIST v1.1
创建时间：
2014-10-15
